Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06467435 · ClinicalTrials.gov registry record · Phase 1
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
A Phase 1 study of Thyroid Eye Disease, sponsored by Peter Timoney.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT06467435: Recruiting Phase 1 study of Thyroid Eye Disease, sponsored by Peter Timoney.
NCT06467435 is a Phase 1 study of Thyroid Eye Disease that is actively recruiting participants, run by Peter Timoney. The registered enrollment target is 13 participants, below the 106-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06467435, a Phase 1 study of Thyroid Eye Disease, is actively recruiting participants, sponsored by Peter Timoney.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.
Primary Outcome
Frequency of participants experiencing ocular or systemic adverse events.
Conditions Studied
Interventions
- DRUG Kamuvudine-9
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2024-11-06 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT06467435 shows while recruiting
NCT06467435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 106-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 1 intervention - of which Kamuvudine-9 is the first listed.
NCT06467435 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06467435 about?
NCT06467435 is a clinical study titled "Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)". The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 w...
What is the current status of trial NCT06467435?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2024-11-06. Estimated completion is 2027-08.
What conditions does trial NCT06467435 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06467435?
The interventions under investigation include: Kamuvudine-9 (DRUG).
Who is sponsoring clinical trial NCT06467435?
This trial is sponsored by Peter Timoney, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06467435 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06467435's enrollment target sits among peer trials
13 15th of 15 higher than 1 of 15 other Thyroid Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
RECRUITING · Phase 1
-
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
RECRUITING · Phase 2
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI